Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
- 专利权人:
- Alex Yeung
- 发明人:
- Yeung, Alex Wah Hin
- 申请号：
- AU2013296919
- 公开号：
- AU2013296919A1
- 申请日:
- 2013.07.22
- 申请国别(地区):
- AU
- 年份:
- 2015
- 代理人:
- 摘要：
- A novel tumor-specific complete vaccine system generated in-vivo. This vaccine system is developed by the use of separated tumor cells inactivated by irradiation and the in-vivo interaction with an oncolytic viral vector with transgenic expression of GM-CSF, completed with immune checkpoint modulators ("ICM") such as co-stimulatory signals confirmation with an anti-CTLA4 antibody. Specifically there will be no pre-incubation or interaction of the either two or all three components before administration to the patient. One of such oncolytic virual vector examples is CG0070 (GM-CSF expressing conditionally replication competent adenovirus). Mixing of the tumor- viral-ICM components will take place just prior to administration to preserve the effects of the oncolytic process and subsequent immunotherapeutic responses to be live and in vivo from the very first beginning. A complete live and in-vivo cancer vaccine system.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- LIVE AND IN-VIVO TUMOR SPECIFIC CANCER VACCINE SYSTEM DEVELOPED BY CO-ADMINISTRATION OF EITHER AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE CHECKPOINT MODULATOR
- LIVE AND IN-VIVO TUMOR SPECIFIC CANCER VACCINE SYSTEM DEVELOPED BY CO-ADMINISTRATION OF EITHER AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE CHECKPOINT MODULATOR
- LIVE AND IN-VIVO TUMOR SPECIFIC CANCER VACCINE SYSTEM DEVELOPED BY CO-ADMINISTRATION OF THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE CHECKPOINT MODULATOR
- LIVE AND IN-VIVO TUMOR SPECIFIC CANCER VACCINE SYSTEM DEVELOPED BY CO-ADMINISTRATION OF EITHER AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE CHECKPOINT MODULATOR
- Live in vivo tumor-specific cancer vaccine system made by co-administration of at least two or all three components such as tumor cells, oncolytic viral vectors with transgenic expression of GM-CSF, and immune checkpoint modulators
